Validity and Reliability of the Turkish Version of the Adult Autism Subthreshold Spectrum Scale.

Authors

Yasemin Hosgoren Alici, Nazlı Burcu Özbaran, Sezen Köse, Aynur Gormez, Ali Kandeğer, Pınar Algedik, Seda Erbaş, Hüseyin Altuğ Yenice, Öykü Mançe Çalışır, Jamal Hasanli, Gonca Asut, Emre Mısır, Zulal Kaya Torenli, Arda Bağcaz, Selvi Ceran, Hande Ayraler Taner, Esra Emekli, Beren Özel, Umut Mert Aksoy, Serhat Tunç, Ece Buyuksandalcı, Yankı Yazgan, Cem Atbaşoğlu

Published in

Intellectual and developmental disabilities. Pages 1-16. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

Considering autism as a spectrum, dimensional measures such as the Adult Autism Subthreshold Spectrum (AdAS Spectrum) have been increasingly emphasized. The AdAS Spectrum is a self-report questionnaire designed to characterize autistic traits and subthreshold manifestations rather than establish an autism diagnosis. This study aimed to culturally adapt the AdAS Spectrum for the Turkish population and evaluate its validity and reliability. A total of 99 individuals with autism spectrum disorder and 348 typically developing participants were enrolled in the study. Participants completed the AdAS Spectrum, Autism Spectrum Quotient (AQ), and Empathy Quotient (EQ) scales. Confirmatory factor analysis supported the seven-domain structure of the original AdAS Spectrum (χ²/df = 2.058, root mean square error of approximation [RMSEA] = 0.048, comparative fit index [CFI] = 0.952, Tucker-Lewis index [TLI] = 0.946, standardized root mean square residual [SRMR] = 0.038). The scale showed high internal consistency (Kuder-Richardson coefficient [KR-20] = 0.964), good-to-excellent test-retest reliability (intraclass correlation coefficient [ICC] = 0.800 through 0.961), and expected associations with another dimensional measure of autistic traits. These findings support the Turkish AdAS Spectrum as a self-report measure for the dimensional characterization of autistic traits in research.

PMID:
42842894
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.